Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.

The effects on linear growth and development among thalassemic patients under different treatment regimens were compared. Twelve homozygous beta-thalassemia (homozygous beta-thal) and 36 beta-thalassemia/Hb E (beta-thal/Hb E) were studied longitudinally between 1977 and 1998. Eighteen cases (10 homozygous beta-thal and 8 beta-thal/Hb E) received hypertransfusion with iron chelation by desferrioxamine. Another 30 cases (2 homozygous beta-thal and 28 beta-thal/Hb E) were given a low transfusion (depending on their clinical requirement). Their heights were measured serially and are presented as a standard deviation score (SDS). There was no significant difference in initial basic hematological data and ferritin levels between either group. However, the hypertransfused group, seemed to be clinically more severely affected than the other group as evidenced by early age at initial transfusion, the early onset of anemia and diagnosis and also their large acquired iron load after a period of transfusion. The average height SDS of the hypertransfused patients was within the 50th percentile +/- 1 SD during the first decade of life in both sexes and both genotypes. Whereas, in patients who were transfused infrequently, the SDS was always below the -1 SD and decreased gradually. In severe beta-thal/Hb E cases, their growth SDS showed no difference from those with homozygous beta-thal. Normal linear growth in those with homozygous beta thal and severe beta-thal/Hb E was only seen in the group that underwent hypertransfusion and this regimen contributed to normal growth during the first ten years of life. However, adequate iron chelation and hormonal treatment in these patients were also required in order to achieve normal adult height.

Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.

During the period 1984-1992, 2 severe cases (1 male, 1 female) of congenital F VII deficiency with intracranial hemorrhage (ICH) were referred to the Department of Pediatrics, Siriraj Hospital Bangkok, Thailand at the ages of 1 and 3 months old. They both responded very well to fresh frozen plasma (FFP) transfusion therapy. Subsequently, both had repeated episodes of ICH (repeated ICH) 5 and 6 times, despite the 10-14 days of replacement therapy for each episode and eventually died at the ages of 11 and 13 months. Since September 1996, another 2 severe cases (2 females) of congenital F VII deficiency who had ICH within their first month of life were referred to us. In order to prevent repeated ICH, we started a prophylactic regime after the second episode of ICH, by giving FFP 10 ml/kg twice a week. The average duration of follow up was 21 months (at 8 and 34 months). All of them (aged 14, and 38 months old) are doing well at this time and free from repeated ICH. From this observation, if there is FFP available, this regime is an effective way to prevent repeated ICH in infants with severe congenital Factor VII deficiency.

Prevalence of HB E from cord blood samples and after one year follow-up.

Hemoglobin (Hb) E is the most prevalent hemoglobinopathy in Southeast Asia. The prevalence of this condition varies from 9-60% of the population in different regions of Thailand and has the highest prevalence the northeast of the country. Neonatal diagnosis of Hb E can be made by detecting the Hb band in cord blood samples at the Hb A2 position using starch gel and cellulose acetate electrophoresis. Our study, performed in Bangkok, in the central part of Thailand, resealed that 182 out of 1,015 cord blood samples (17.9%) contained Hb E in amounts of between 1.9 and 10.0%. The cases who had Hb A, F and E with or without Hb Bart's were initially included in the study. These cases were suspected to have the Hb E trait. One hundred and seven cases (58.89%) were available for follow up and in all of these, Hb E could be detected throughout the study. A sharp increase in the amount of Hb E was observed at the 3 months follow-up appointment. One year follow-up could be made in 72 cases (39.6%) when the percentage of Hb E was around 25%. We conclude that measurement of Hb E in cord blood an easily accessible, simple, practical and sensitive procedure which can be used to study the Hb E hemoglobinopathy which is widely distributed in Thailand and Southeast Asia.